97296 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Monoclonal antibodies to gastrin hormone
#5702Cytokine zalpha11 ligand fusion proteins
#5703Cytokine zalpha11 ligand fusion proteins
#5704Molecular determinants of myeloma bone disease and use thereof
#5705Methods and compositions for treating diseases targeting MABA1
#5706Compositions and methods for treating hyperimmune response in the eye
#5707Tumor necrosis factor binding ligands
#5708Epithelial cell specific growth factor keratinocyte growth factor (KGF)
#5709Method for expanding hematopoietic cells using cytokine zalpha11 ligand
#5710Method and compositions for the treating diseases targeting E-cadherin
#5711Anti-VEGF antibodies
#5712Regulation of the hedgehog signaling pathway and uses thereof
#5713CD37 immunotherapeutics and uses thereof
#5714Neutralizing human anti-IGFR antibody
#5715ANTI-VEGF ANTIBODIES
#5716METHODS OF TREATING INFECTIONS USING IL-21
#5717Neutralizing human anti-IGFR antibody
#5718Recombinant production of mixtures of antibodies
#5719Compositions and methods for modulating immune responses
#5720Cytokine zalpha11 ligand antibodies and methods of use
#5721Antitumor antibodies, proteins, and uses thereof
#5722Methods of using pHHLA2 to co-stimulate T-cells
#5723Cytotoxicity mediation of cells evidencing surface expression of CD44
#5724METHODS OF TREATING CANCER USING IL-21
#5725METHODS OF TREATING CANCER USING IL-21
#5726Methods of using cytokine zalpha11 ligand
#5727CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS
#5728SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
#5729COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR
#5730Compositions and Methods for the Diagnosis and Treatment of Tumor
#5731Combination therapies for inhibiting integrin-extracellular matrix interactions
#5732Antitumor antibodies, proteins, and uses thereof
#5733Engineered anti-IL-23 antibodies
#5734Method of treating allergy using antibody against human interleukin-5 receptor alpha chain
#5735Method of inducing SHC phosphorylation of inducing the SHC/MAPK pathway by administering a peptide of IL-2
#5736Methods of treating cancer using IL-21
#5737Methods of treating cancer using IL-21
#5738Methos of treating cancer using IL-21
#5739METHODS OF TREATING CANCER USING IL-21
#5740METHODS OF TREATING CANCER USING IL-21
#5741METHODS OF TREATING CANCER USING IL-21
#5742METHODS OF TREATING CANCER USING IL-21
#5743METHODS OF TREATING CANCER USING IL-21
#5744Cytokine zalpha11 ligand fusion proteins
#5745Method of use of cytokine ZALPHA11 ligand
#5746SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
#5747CA6 antigen-specific cytotoxic conjugate and methods of using the same
#5748CYTOKINE ZALPHA11 LIGAND ANTIBODIES
#5749WISP polypeptides and nucleic acids encoding same
#5750METHODS OF TREATING CANCER USING IL-21
#5751Methods of treating brain tumors with antibodies
#5752Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
#5753Novel protein related to melanoma-inhibiting protein and uses thereof
#5754Cancerous disease modifying antibodies
#5755Cancerous disease modifying antibodies
#5756Cancerous disease modifying antibodies
#5757Cancerous disease modifying antibodies
#5758Cancerous disease modifying antibodies
#5759Antibodies to treat cancer
#5760Inhibitors targeting osteoclast-associated protein
#5761Methods and compositions for treating diseases targeting CDCP1
#5762Cancerous disease modifying antibodies
#5763Specificity exchangers that redirect antibodies to a pathogen
#5764Human cancer-relating genes, the products encoded thereby and applications thereof
#5765Inhibitors of angiopoietin-like 4 protein, combinations, and their use
#5766Methods for using human monoclonal antibodies to interleukin-5
#5767Method of preventing or reducing the likelihood of pregnancy
#5768Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
#5769Endothelial cell specific antibodies and uses thereof
#5770Anti-VEGF antibodies
#5771Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
#5772Cytokine zalpha11 ligand antibodies
#5773Antibodies which activate an erythropoietin receptor
#5774Antibodies directed to CD20 and uses thereof
#5775Methods for treating fibrotic conditions
#5776Methods for obtaining antibodies
#5777Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
#5778Modified antibodies against cd22 and utilization thereof
#5779Human IGM monoclonal antibody capable of inducing apoptosis in HIV-infected cells
#5780T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
#5781Nucleic acids encoding superagonistic anti-CD28 antibodies
#5782Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
#5783Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
#5784Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
#5785Modulation of NKG2D for treating or preventing solid organ allograft rejection
#5786Anti-VEGF antibodies
#5787Peptides modulating caspase activation
#5788Antibodies to treat cancer
#5789Cell death-inducing agent
#5790Host cells expressing 7C10 and 16C10 CD80-specific antibodies
#5791Antibodies and related molecules that bind to 161P2F10B proteins
#5792Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
#5793Antibodies that immunospecifically bind to TRAIL receptors
#5794Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
#5795Humanized anti-CD3 specific antibodies
#5796Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
#5797Antibodies to treat cancer
#5798Targeted chimeric molecules for cancer therapy
#5799Neoplasm specific antibodies and uses thereof
#5800Nucleolin-mediated cancer diagnostics and therapy
#5801Antitumorigenic drug combination and dosing schedule
#5802Extracellular matrix signalling molecules
#5803Anti-il-6 antibodies, compositions, methods and uses
#5804Method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
#5805Antibodies to TGF-β
#5806CD20 binding molecules
#5807Apo-2 receptor
#5808Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2
#5809Use of antibodies against the MUC18 antigen
#5810Antibody variants and uses thereof
#5811Genetically engineered glutaminase and its use in antiviral and anticancer therapy
#5812Individualized anti-cancer antibodies
#5813Recombinant antibody against human insulin-like growth factor
#5814Human antihuman interleukin-6 antibody and fragment of antibody
#5815Truncated baff receptors
#5816Peptabody for cancer treatment
#5817Tumour necrosis factor binding ligands
#5818Human cd3-specific antibody with immunosuppressive properties
#5819Constructs binding to phosphatidylserine and their use in disease treatment
#5820Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
#5821Methods for inducing antigen-specific T cell tolerance
#5822Nanoparticles for therapeutic and diagnostic applications
#5823Compositions and methods for promoting or inhibiting angiogenesis
#5824Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
#5825Cytotoxicity mediation of cells evidencing surface expression of CD44
#5826Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
#5827Humanized L243 antibodies
#5828VEGF-conjugate combined methods for tumor vasculature targeting and tumor treatment
#5829Compositions comprising a first agent which provides a primary activation signal to T cells and a second agent which stimulates an accessory molecule on the surface of T cells
#5830Use of hepatitis B X-interacting protein (HBXIP) in modulation of apoptosis
#5831Tumour necrosis factor binding ligands
#5832Methods for modulating T cell survival by modulating bcl-XL protein level
#5833Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
#5834Treatment with anti-ErbB2 antibodies and chemotherapeutic agents
#5835Compositions and methods for diagnosing and treating prostate cancer
#5836Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
#5837Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
#5838Anti-IL-6 antibodies, compositions, methods and uses
#5839Diagnostic and therapeutic agents for rheumatoid arthritis
#5840Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer
#5841Human monoclonal antibodies to epidermal growth factor receptor
#5842Tumour necrosis factor binding ligands
#5843Apo-2 receptor antibodies
#5844Antibodies that bind to EphA2 and methods of use thereof
#5845Antibody and use thereof
#5846Inhibiting HER2 shedding with matrix metalloprotease antagonists
#5847Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
#5848Method of treating CD30 positive lymphomas
#5849Techniques and compositions for diagnosis and treatment of cancer (muci)
#5850ADAM-9 modulators
#5851LUCA2 and antibodies that bind thereto
#5852JAM-3 and antibodies that bind thereto
#5853Antibodies to oncostatin M receptor
#5854USE OF CD23 ANTAGONISTS FOR THE TREATMENT OF NEOPLASTIC DISORDERS
#5855Compositions and methods for the treatment and prevention of hyperproliferative diseases
#5856Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
#5857Antibody against human insulin-like growth factor
#5858Humanized anti-CD3 specific antibodies
#5859Humanized anti-CD3 specific antibodies
#5860Humanized anti-CD3 specific antibodies
#5861Compositions and methods for the diagnosis and treatment of tumor
#5862Polynucleotides encoding BSL2v1c2-Ig
#5863Tumour necrosis factor peptide binding antibodies
#5864Antibodies to M-CSF
#5865Treating autoimmune diseases with humanized anti-CD401 antibodies
#5866Humanized antibodies to human GP39, compositions, and therapeutic uses thereof
#5867Antibodies and related molecules that bind to PSCA proteins
#5868Antibodies specific for TAT285-1
#5869Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
#5870Pharmaceutical compositions comprising an hiv envelope protein and cd4
#5871Tumour necrosis factor binding ligands
#5872Tumour necrosis factor binding ligands
#5873Fully human monoclonal antibodies to IL-13
#5874Polypeptides involved in immune response
#5875Anti-IL-20 antibodies and binding partners and methods of using in inflammation
#5876Methods for regulating cancer
#5877Humanized anti-cmet antibodies
#5878Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
#5879Anti-integrin immunoconjugates, methods and uses
#5880Rapamycin and il-10 for the treatment of immune diseases
#5881Specific binding agents of human angiopoietin-2
#5882Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
#5883Apo-2 receptor polynucleotides
#5884Disease treatment via antimicrobial peptide inhibitors
#5885Treatment of disease with antibodies against high molecular weight kininogen domain 5
#5886Porcine reproductive and respiratory syndrome virus receptor components and uses thereof
#5887Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
#5888Bifunctional energy-reversible acyl-compositions
#5889Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
#5890Enhancement of B cell proliferation by IL-15
#5891Specificity exchangers that redirect antibodies to a pathogen
#5892Inhibitors of angiopoietin-like 4 protein, combinations, and their use
#5893ErbB4 antagonists
#5894Antagonists and methods for inhibiting angiogenesis
#5895Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
#5896Humanized anti-CD3 specific antibodies
#5897Therapeutic binding molecules
#5898Duffy antigen receptor for chemokines and use thereof
#5899Apo-2 receptor
#5900TWEAK receptor
#5901Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
#5902Treating prostate cancer with anti-ErbB2 antibodies
#5903Antigen-presenting complex-binding compositions and uses thereof
#5904Neoplasm specific antibodies and uses thereof
#5905Treatment of cancer using anti-Apo-2 antibodies
#5906Individualized anti-cancer antibodies
#5907Individualized anti-cancer antibodies
#5908Treatment with anti-ErbB2 antibodies and anti-hormonal compounds
#5909Survivin, a protein that inhibits cellular apoptosis, and its modulation
#5910Survivin, a protein that inhibits cellular apoptosis, and its modulation
#5911Antagonists specific for denatured collagen and methods of using same
#5912Antibodies against human interleukin-13 and pharmaceutical compositions thereof
#5913Modified antibodies to prostate-specific membrane antigen and uses thereof
#5914Method for determining MIF content
#5915Influencing angiogenesis using CD66a
#5916Method of inhibition of vascular development using an antibody
#5917Method for NGF assay for in vitro diagnosis of breast cancer and therapeutic use
#5918Humanized anti-CD4 antibody with immunosuppressive properties
#5919Fusion proteins of humanized g250 specific antibodies and uses thereof
#5920Apo-3 polypeptide
#5921Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
#5922Use of Smad3 inhibitor in the treatment of fibrosis dependent on epithelial to mesenchymal transition as in the eye and kidney
#5923P-cadherin as a target for anti-cancer therapy
#5924Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
#5925Method and compositions for treating diseases targeting CD71
#5926Apo-2 receptor polypeptides
#5927Method and compositions for treating diseases targeting CD51
#5928Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
#5929Stimulation of T cells against self antigens using CTLA-4 blocking agents
#5930Treatment with anti-ErbB2 antibody combinations
#5931ErbB antagonists for pain therapy
#5932Enhancing the circulating half-life of antibody-based fusion proteins
#5933Immunoglobulin variants and uses thereof
#5934Methods for downmodulating immune cells using an antibody to PD-1
#5935Method and compositions for treating diseases targeting E-cadherin
#5936Prevention and treatment of cardiovascular pathologies
#5937Prostate stem cell antigen (PSCA) variants and subsequences thereof
#5938Methods and compositions for modulating tumor growth
#5939IgA antibody protein as a cytotoxic drug
#5940Multivalent antibodies and uses therefor
#5941Methods for producing antibody compositions with increased ADCC
#5942Anti-viral activity of an anti-thymidine kinase monoclonal antibody
#5943Methods of treating and preventing colitis involving IL-13 and NK-T cells
#5944Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
#5945Immunoglobulin variants and uses thereof
#5946Antibodies to Tie1 ectodomain
#5947Therapeutic use of anti-CS1 antibodies
#5948Monoclonal antibodies to gastrin hormone
#5949CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
#5950Therapeutic use of anti-TF-Antigen antibody
#5951Angiopoietin-2 specific binding agents
#5952HER2 antibody composition
#5953Method for inducing selected useful activities of IL-2 in a patient with peptides from IL-2
#5954Screening assays and methods of tumor treatment
#5955Methods for treating HIV infected subjects
#5956Anti-CD40CR MR1 antibody
#5957Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL
#5958Calicheamicin conjugates
#5959Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria
#5960Monoclonal antibodies
#5961Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
#5962Autophilic antibodies
#5963Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
#5964Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
#5965Methods for identifying functional antibodies
#5966Cell growth inhibitor containing anti-PepT antibody
#5967Antibodies against human IL-12
#5968Method and composition for angiogenesis inhibition
#5969Antibodies to insulin-like growth factor I receptor
#5970Anti-lymphotoxin-β receptor antibodies as anti-tumor agents
#5971Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
#5972Method of modulating the activity of functional immune molecules
#5973Humanized anti-TGF-beta antibodies
#5974Method of treating atopic dermatitis using antibody against human interleukin-5 receptor alpha chain
#5975Method of modulating the activity of functional immune molecules
#5976Compositions and methods for the diagnosis and treatment of tumor
#5977Compositions and methods for treating inflammatory disorders
#5978Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
#5979Antibody compositions
#5980Antibodies and uses thereof
#5981Anti-PSGL-1 antibodies
#5982Therapeutic blockade of CD103 interactions to prevent clinical renal allograft rejection
#5983Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#5984Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#5985Use of anti-α5β1 antibodies to inhibit cancer cell proliferation
#5986CD80 specific antibodies
#5987Method for treating cancer and identifying novel anti-cancer compounds
#5988Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
#5989Methods and composition for treating tumors and metastatic disease
#5990Cripto-specific antibodies
#5991Methods and compositions for inhibition of metastasis
#5992Anti-αβantibodies
#5993Polypeptide compounds for inhibiting angiogenesis and tumor growth
#5994Anti-TRAIL-R antibody
#5995Anti-IGF-I receptor antibody
#5996Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
#5997Expression of functional antibody fragments
#5998Pharmaceutical composition and method for activating macrophage using the same
#5999Antibodies to insulin-like growth factor I receptor
#6000Therapeutic synergy of anti-cancer compounds